[HTML][HTML] Clinical findings and pain symptoms as potential risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case …

R Ohrbach, RB Fillingim, F Mulkey, Y Gonzalez… - The Journal of …, 2011 - Elsevier
Clinical characteristics might be associated with temporomandibular disorders (TMD)
because they are antecedent risk factors that increase the likelihood of a healthy person …

[HTML][HTML] Pain sensitivity risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case control study

…, RB Fillingim, R Ohrbach, C Knott, F Mulkey… - The Journal of …, 2011 - Elsevier
Many studies report that people with temporomandibular disorders (TMD) are more sensitive
to experimental pain stimuli than TMD-free controls. Such differences in sensitivity are …

[HTML][HTML] Study methods, recruitment, sociodemographic findings, and demographic representativeness in the OPPERA study

GD Slade, E Bair, F Mulkey, C Baraian, R Rothwell… - The Journal of …, 2011 - Elsevier
This paper describes methods used in the project “Orofacial Pain Prospective Evaluation and
Risk Assessment” (OPPERA) and evaluates sociodemographic characteristics associated …

[HTML][HTML] Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning …

SM Devine, K Owzar, W Blum, F Mulkey… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Purpose Long-term survival rates for older patients with newly diagnosed acute myeloid
leukemia (AML) are extremely low. Previous observational studies suggest that allogeneic …

[HTML][HTML] Potential autonomic risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case-control study

…, JD Greenspan, R Dubner, E Bair, F Mulkey… - The Journal of …, 2011 - Elsevier
Several case-control studies have been conducted that examine the association between
autonomic variables and persistent pain conditions; however, there is a surprising dearth of …

[HTML][HTML] FDA approval summary: abemaciclib with endocrine therapy for high-risk early breast cancer

M Royce, C Osgood, F Mulkey… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE The US Food and Drug Administration approved abemaciclib in combination with
endocrine therapy (ET) for the adjuvant treatment of adult patients with hormone receptor–…

Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials

SL Mushti, F Mulkey, R Sridhara - Clinical Cancer Research, 2018 - AACR
Purpose: With the approval of immunotherapies for a variety of indications, methods to assess
treatment benefit addressing the response patterns observed are important. We evaluated …

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis

JA Beaver, M Hazarika, F Mulkey, S Mushti… - The Lancet …, 2018 - thelancet.com
Background Patients who receive immunotherapeutic drugs might develop an atypical
response pattern, wherein they initially meet conventional response criteria for progressive …

[HTML][HTML] Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation …

M Wetzler, D Watson, W Stock, G Koval, FA Mulkey… - …, 2014 - ncbi.nlm.nih.gov
Allogeneic stem cell transplantation is the standard approach to Philadelphia chromosome
positive acute lymphoblastic leukemia. We hypothesized that imatinib plus sequential …

Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a US Food and Drug Administration …

KJ Norsworthy, F Mulkey, EC Scott, AF Ward… - Clinical Cancer …, 2020 - AACR
Purpose: Differentiation syndrome (DS) is a serious adverse reaction of isocitrate
dehydrogenase (IDH) inhibitors ivosidenib and enasidenib in patients with (IDH)1- and IDH2-mutated …